Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | PAM | P19021 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570308 | 0.91 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL13291851 | 0.87 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL4911689 | 0.85 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL1434644 | 0.83 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL28395073 | 0.83 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL3396096 | 0.82 | LMNA (0.66) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL8180121 | 0.82 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL4207976 | 0.81 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL456516 | 0.81 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MAPK1PAMTDP1 | |
| SCHEMBL27546859 | 0.81 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MAPK1PAMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | ALDH1A1 3290/4885L3MBTL1 3174/4885MAPK1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.